- Conditions
- Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- agenT-797
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Condition Directory
Acute Myeloid Leukemia clinical trials
Directory of U.S. ClinicalTrials.gov public records for Acute Myeloid Leukemia. Browse Acute Myeloid Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2504
Shown on this page
12
Current sort
Recently updated
Condition scope
Acute Myeloid Leukemia
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Acute Myeloid Leukemia studies are organized in the registry
AML records split between newly diagnosed and relapsed/refractory settings, and a meaningful share are defined by a mutation — FLT3, IDH1, IDH2, NPM1 — that appears verbatim in titles. Age language (“older adults,” “unfit for intensive chemotherapy”) is also common and reflects how the field organizes its studies.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 73–84 of 2,504 matching trials for Acute Myeloid Leukemia.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
- Interventions
- Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI
- Procedure · Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C)
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 44
- States / cities
- Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
- Interventions
- Busulfan, Melphalan, Fludarabine, CD34+ Allogeneic Peripheral Blood Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- Guenther Koehne
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2034
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 135
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Fludarabine, Busulfan, ATG, Total Marrow Irradiation, Stem Cell Product Infusion, Tacrolimus, Methotrexate
- Drug · Radiation · Procedure
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Luveltamab tazevibulin
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 1 Day to 12 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
- Conditions
- Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
- Interventions
- Maintenance Therapy, No intervention
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CLL-1.CAR T cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Active Default
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Day to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2099
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Interventions
- Azacitidine, Rezatapopt
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Houston, Texas
About this Acute Myeloid Leukemia clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Acute Myeloid Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acute Myeloid Leukemia.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Acute Myeloid Leukemia.